MedTrace Logo

Intensive Cancer Screening After Cryptogenic Stroke

NCT05733416 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-07-31

No results posted yet for this study

Summary

The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.

Conditions

  • Occult Cancer

Interventions

DIAGNOSTIC_TEST

FDG PET/CT

F-fluorodeoxyglucose positron emission/computed tomography

DIAGNOSTIC_TEST

Usual Care

Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care

Sponsors & Collaborators

  • Brain Canada

    collaborator OTHER

  • Heart and Stroke Foundation of Canada

    collaborator OTHER

  • Canadian Stroke Consortium (CSC)

    collaborator OTHER

  • Ottawa Hospital Research Institute

    lead OTHER

Principal Investigators

  • Dariush Dowlatshahi, MD PhD · Ottawa Hospital Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-01
Primary Completion
2027-01-31
Completion
2027-01-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05733416 on ClinicalTrials.gov